BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 3.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,264,880 | +150.0% | 3,286,000 | +148.6% | 0.51% | +157.8% |
| Q2 2023 | $9,306,880 | -59.6% | 1,322,000 | -52.2% | 0.20% | -61.3% |
| Q1 2023 | $23,060,100 | +40.1% | 2,765,000 | +173.2% | 0.51% | +39.7% |
| Q1 2022 | $16,455,000 | -29.5% | 1,012,000 | -40.0% | 0.37% | -24.9% |
| Q4 2021 | $23,353,000 | +592.6% | 1,686,140 | +618.6% | 0.49% | +642.4% |
| Q3 2021 | $3,372,000 | -92.5% | 234,643 | -91.7% | 0.07% | -91.7% |
| Q2 2021 | $44,821,000 | +69.2% | 2,835,000 | +8.8% | 0.80% | +42.9% |
| Q1 2021 | $26,497,000 | -39.1% | 2,605,380 | -55.4% | 0.56% | -35.2% |
| Q4 2020 | $43,477,000 | +184.0% | 5,835,810 | +30.9% | 0.86% | +130.3% |
| Q3 2020 | $15,308,000 | -27.9% | 4,456,519 | 0.0% | 0.37% | -39.6% |
| Q2 2020 | $21,235,000 | +128.2% | 4,456,519 | -4.2% | 0.62% | +109.5% |
| Q1 2020 | $9,306,000 | -57.7% | 4,652,926 | -27.0% | 0.30% | -58.0% |
| Q4 2019 | $21,994,000 | +176.7% | 6,375,143 | +129.8% | 0.70% | +116.7% |
| Q3 2019 | $7,949,000 | -66.7% | 2,774,643 | -55.9% | 0.32% | -62.2% |
| Q2 2019 | $23,850,000 | -55.2% | 6,292,980 | -3.7% | 0.86% | -58.0% |
| Q1 2019 | $53,216,000 | -4.6% | 6,537,566 | -5.4% | 2.04% | -8.6% |
| Q4 2018 | $55,770,000 | +5.8% | 6,910,789 | 0.0% | 2.23% | +18.2% |
| Q3 2018 | $52,729,000 | +51.8% | 6,910,789 | +14.0% | 1.89% | +54.8% |
| Q2 2018 | $34,744,000 | -1.1% | 6,063,496 | -17.7% | 1.22% | +0.2% |
| Q1 2018 | $35,138,000 | -0.8% | 7,366,460 | +2.1% | 1.22% | -12.7% |
| Q4 2017 | $35,418,000 | +35.9% | 7,213,393 | +45.0% | 1.39% | +18.7% |
| Q3 2017 | $26,071,000 | +17.2% | 4,975,451 | +24.4% | 1.17% | -1.0% |
| Q2 2017 | $22,236,000 | -14.2% | 3,999,202 | +29.6% | 1.19% | +18.6% |
| Q1 2017 | $25,916,000 | +26.5% | 3,085,236 | -4.7% | 1.00% | +18.6% |
| Q4 2016 | $20,495,000 | +5.6% | 3,237,734 | -26.4% | 0.84% | -6.6% |
| Q3 2016 | $19,412,000 | +102.1% | 4,401,846 | +384.8% | 0.90% | +130.4% |
| Q1 2014 | $9,606,000 | +45.5% | 907,920 | +4.5% | 0.39% | +14.6% |
| Q4 2013 | $6,601,000 | -44.5% | 868,570 | -46.8% | 0.34% | -38.2% |
| Q3 2013 | $11,884,000 | – | 1,632,360 | – | 0.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |